Lenzilumab
As of the edition of 20 October 2026, Lenzilumab is an antibody: stopped in 2022; acts on CSF2.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2022
- Kind
- Antibody
- Registered trials
- 6, 2 stopped early
- Disease areas
- Infections; Lungs and airways; Cancer; Blood and lymph; Bones, joints and muscles; Immune system
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
2 companies on route A because of this drug.
Companies on route A for this drug
In the product2 companies are on route A because of Lenzilumab.
See the 2 companies on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| CSF2 | Granulocyte-macrophage colony-stimulating factor | P04141 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 2 | 1 | 0 | 1 |
| Phase 2 | 2 | 1 | 0 | 1 |
| Phase 3 | 2 | 1 | 0 | 0 |
| All trials | 6 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Humanigen | Lead sponsor of trials | 2010 to now |
| Gilead Sciences | Lead sponsor of trials | 2020 to now |